• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Wednesday, August 6, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Immunology

X-factor to help antibiotics regain their spark

Bioengineer by Bioengineer
February 23, 2021
in Immunology
Reading Time: 3 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Holding off the rise of superbugs could be achieved by ‘resuscitating’ old antibiotics.

IMAGE

Credit: Institute for Molecular Bioscience, UQ

Holding off the rise of superbugs could be achieved by ‘resuscitating’ old antibiotics, with The University of Queensland researchers leading an international project to help combat the growing threat.

CARB-X, a global non-profit partnership funding the world’s largest antibacterial development pipeline, has funded the $AU2.9m project at UQ’s Institute for Molecular Bioscience (IMB).

Associate Professor Mark Blaskovich, Dr Alysha Elliott and Dr Johannes Zuegg will assess which antibiotics that are losing their effectiveness could be revived by combining them with a compound from a new family of antibiotics.

“We are running out of time to outsmart the most dangerous drug-resistant bacteria, the sort of infections that can cause deadly bacterial sepsis, pneumonia, urinary tract and wound infections,” Dr Blaskovich said.

“Compounds from a group known as the Octapeptins could be the spark the older drugs need to reinvigorate them as they act to disrupt the bacteria’s cell membrane–making it easier for the antibiotic to gain access.”

Dr Elliott said these ‘potentiators’ had been shown to help some antibiotics regain their activity against bacteria which have developed high levels of drug resistance, and reduce the amount of the antibiotic required to effectively kill bacteria by up to 100-fold.

“The benefit is that we can potentially restore the use of cheap generic antibiotics that are widely used in low and middle income countries, where there are high levels of drug-resistant bacteria,” Dr Elliott said.

“We will also share our expertise and technologies with researchers in countries such as Pakistan, Nepal, Egypt, Nigeria, Brazil, Thailand and Indonesia so they can genetically sequence resistant bacteria strains in real-time as they emerge.”

Dr Blaskovich said resistance to current antibiotics was increasing at an alarming rate, highlighting the urgent need for innovative solutions.

“With time of the essence, we are appreciative of the support of CARB-X to accelerate UQ’s IMB Centre for Superbug Solutions’ many-pronged attack on this global threat to human health,” Dr Blaskovich said.

###

The current project builds on the first Australian and first University CARB-X award to the Centre for Superbug Solutions in 2020 to develop the Octapeptin class as a stand-alone antibiotic treatment, led by Prof Matthew Cooper and Dr Karl Hansford along with Dr Blaskovich.

CARB-X receives its funding from the US Biomedical Advanced Research and Development Authority (BARDA), the Wellcome Trust in the UK, Germany’s Federal Ministry of Education and Research (BMBF), the UK Global Antimicrobial Resistance (AMR) Innovation Fund (GAMRIF), and the Bill & Melinda Gates Foundation. Funding contributions by GAMRIF are earmarked by CARB-X to fund projects that focus on specific antibacterial priorities, and the UQ IMB Octapeptin LMIC project is one such project. GAMRIF funding allocated to CARB-X is focused on innovative research and development in the field of AMR, specifically in underinvested areas for LMICs, where the burden of AMR is greatest.

VIDEO:

https://youtu.be/DYYCGTa1gCY

Media Contact
Dr Jane Ilsley
[email protected]

Original Source

https://imb.uq.edu.au/article/2021/02/x-factor-help-antibiotics-regain-their-spark

Tags: BacteriologyDisease in the Developing WorldHealth CareInfectious/Emerging DiseasesMedicine/HealthMicrobiologyPublic Health
Share12Tweet8Share2ShareShareShare2

Related Posts

IMAGE

UMass Amherst grad student awarded fellowship for food allergy research

July 23, 2021
IMAGE

Less-sensitive COVID-19 tests may still achieve optimal results if enough people tested

July 22, 2021

Public trust in CDC, FDA, and Fauci holds steady, survey shows

July 20, 2021

USC study shows male-female differences in immune cell function

July 19, 2021
Please login to join discussion

POPULAR NEWS

  • blank

    Neuropsychiatric Risks Linked to COVID-19 Revealed

    75 shares
    Share 30 Tweet 19
  • Overlooked Dangers: Debunking Common Myths About Skin Cancer Risk in the U.S.

    61 shares
    Share 24 Tweet 15
  • Predicting Colorectal Cancer Using Lifestyle Factors

    46 shares
    Share 18 Tweet 12
  • Dr. Miriam Merad Honored with French Knighthood for Groundbreaking Contributions to Science and Medicine

    47 shares
    Share 19 Tweet 12

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Eugenol’s Anti-Leishmanial Potential Explored In Vitro

Neonatal Care Innovations and Challenges in 21st Century

Advances and Challenges in Nanostructured Breast Cancer Therapy

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.